PCVX FY 2025 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$924M

Net Income

-$767M

EPS (Diluted)

$-5.63

Cash Flow

Operating Cash Flow

-$656M

Free Cash Flow

-$669M

Stock-Based Comp.

$139M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$360M

Stockholders' Equity

$2.7B

Cash & Equivalents

$174M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$924M	-$570M	-62.2%
Net Income	-$767M	-$464M	-65.2%